Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: A multi-centre longitudinal study

Diabetes, Obesity and Metabolism

Volumn 16, Issue 3, 2014, Pages 262-267

  Barker, A ^a   Lauria, A ^b   Schloot, N ^c,m   Hosszufalusi, N ^d   Ludvigsson, J ^e   Mathieu, C ^f   Mauricio, D ^g   Nordwall, M ^e,h   Van der Schueren, B ^f   Mandrup Poulsen, T ⁱ   Scherbaum, W A ^c   Weets, I ^j,k   Gorus, F K ^j,k   Wareham, N ^a   Leslie, R D ^l   Pozzilli, P ^b,l  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^e LINKÖPING UNIVERSITY   (Sweden)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g HOSPITAL ARNAU DE VILANOVA   (Spain)

^h VRINNEVI HOSPITAL   (Sweden)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j DIABETES RESEARCH CENTER   (Belgium)

^k Belgian Diabetes Registry   (Belgium)

^l QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^m LILLY DEUTSCHLAND GMBH   (Germany)

more..

Author keywords

Clinical trial; Type 1 diabetes; cell

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; HEMOGLOBIN A1C; LONG ACTING INSULIN;

ADOLESCENT; ADULT; AGING; ARTICLE; CHILD; CLINICAL TRIAL (TOPIC); CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DIET RESTRICTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LABORATORY TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; ONSET AGE; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

CLINICAL TRIAL; TYPE 1 DIABETES; Β CELL;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; AGING; BIOLOGICAL MARKERS; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ANTIBODIES; INSULIN-SECRETING CELLS; LONGITUDINAL STUDIES; MALE;

EID: 84893798821     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12216     Document Type: Article

References (40)

1. Palmer JP, Fleming GA, Greenbaum CJ et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004; 53: 250-264.
2. Cernea S, Raz I, Herold K et al. D-Cure Workshop Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev 2009; 25: 694-704.
3. Ludvigsson J. C-peptide an adequate endpoint in type 1 diabetes. Diabetes Metab Res Rev 2009; 25: 691-693.
4. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.
5. Pozzilli P. Type 1 diabetes mellitus in 2011: heterogeneity of T1DM raises questions for therapy. Nat Rev Endocrinol 2011; 8: 78-80.
6. Orban T, Bundy B, Becker DJ et al, Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378: 412-419.
7. Sherry N, Hagopian W, Ludvigsson J et al. Protege Trial I. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378: 487-497.
8. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608.
9. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the diabetes control and complications trial (DCCT). J Clin Endocrinol Metab 1987; 65: 30-36.
10. Gjessing HJ, Matzen LE, Frøland A, Faber OK. Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics. Diabetes Care 1987; 10: 487-490.
11. Daneman D, Clarson C. Residual beta-cell function in children with type 1 diabetes: measurement and impact on glycemic control. Clin Invest Med 1987; 10: 484-487.
12. Hendriksen C, Faber OK, Drejer J, Binder C. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia 1977; 13: 615-619.
13. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977; 26: 605-610.
14. Garcia-Webb P, Bonser A, Welborn TA. Correlation between fasting serum C-peptide and B cell insulin secretory capacity in diabetes mellitus. Diabetologia 1982; 22: 296.
15. Greenbaum CJ, Beam CA, Boulware D et al., Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during first 2years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012; 61: 2066-2073.
16. Dabelea D, Mayer-Davis EJ, Andrews JS et al. Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study. Diabetologia 2012; 55: 3359-3368.
17. Herold KC, Gitelman SE, Masharani U et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2years after onset of type 1 diabetes. Diabetes 2005; 54: 1763-1769.
18. Klinke DJ 2nd. Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans. PLoS One 2011; 6: e26873.
19. Pipeleers D, Ling Z. Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 1992; 8: 209-227.
20. Mortensen HB, Swift PG, Holl RW, Hougaard P et al, Hvidoere Study Group on Childhood Diabetes. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12months after diagnosis. Pediatr Diabetes 2010; 11: 218-226.
21. Bonfanti R, Bazzigaluppi E, Calori G et al. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with type 1 diabetes mellitus. Diabet Med 1998; 15: 844-850.
22. Howson JM, Rosinger S, Smyth DJ, Boehm BO, Group A-ES, Todd JA. Genetic analysis of adult-onset autoimmune diabetes. Diabetes 2011; 60: 2645-2653.
23. Heimberg H, Nagy ZP, Somers G, De Leeuw I, Schuit FC. Complementation of HLA-DQA and -DQB genes confers susceptibility and protection to insulin-dependent diabetes mellitus. Hum Immunol 1992; 33: 10-17.
24. Vandewalle CL, Decraene T, Schuit FC, De Leeuw IH, Pipeleers DG, Gorus FK. Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1*0301-DQB1*0302 haplotype at clinical type 1 (insulin-dependent) diabetes mellitus before age 10years, but not at onset between age 10 and 40years. The Belgian Diabetes Registry. Diabetologia 1993; 36: 1155-1162.
25. Kockum I, Lernmark A, Dahlquist G et al. Genetic and immunological findings in patients with newly diagnosed insulin-dependent diabetes mellitus. The Swedish Childhood Diabetes Study Group and The Diabetes Incidence in Sweden Study (DISS) Group. Horm Metab Res 1996; 28: 344-347.
26. Lohmann T, Sessler J, Verlohren HJ et al. Distinct genetic and immunological features in patients with onset of IDDM before and after age 40. Diabetes Care 1997; 20: 524-529.
27. Graham J, Kockum I, Sanjeevi CB et al. Negative association between type 1 diabetes and HLA DQB1*0602-DQA1*0102 is attenuated with age at onset. Swedish Childhood Diabetes Study Group. Eur J Immunogenet 1999; 26: 117-127.
28. Awata T, Hagura R, Urakami T, Kanazawa Y. Age-dependent HLA genetic heterogeneity of IDDM in Japanese patients. Diabetologia 1995; 38: 748-749.
29. Decochez K, Keymeulen B, Somers G et al, Belgian Diabetes Registry. Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry. Diabetes Care 2000; 23: 1072-1078.
30. Meier JJ, Butler AE, Saisho Y et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 2008; 57: 1584-1594.
31. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008; 173: 600-609.
32. Schatz DA, Winter WE. Autoimmune polyglandular syndrome. II: Clinical syndrome and treatment. Endocrinol Metab Clin North Am 2002; 31: 339-352.
33. Ludvigsson J, Krisky D, Casas R et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366: 433-442.
34. Kyvik KO, Nystrom L, Gorus F et al. The epidemiology of Type 1 diabetes mellitus is not the same in young adults as in children. Diabetologia 2004; 47: 377-384.
35. Vandewalle CL, Coeckelberghs MI, De Leeuw IH et al. Epidemiology, clinical aspects, and biology of IDDM patients under age 40years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry. Diabetes Care 1997; 20: 1556-1561.
36. Weets I, Truyen I, Verschraegen I et al. Belgian Diabetes Registry Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes. Diabetologia 2006; 49: 1158-1162.
37. Samuelsson U, Lindblad B, Carlsson A et al, Better Diabetes Diagnosis (BDD) study group. Residual beta cell function at diagnosis of Type 1 diabetes in children and adolescents varies with gender and season. Diabetes Metab Res Rev 2013; 29: 85-89.
38. Gottlieb PA, Pozzilli P. DEFEND presented during session: Treatment of type 1 diabetes - update on clinical trials. ADA 71st Scientific Sessions, San Diego, California, June 28, 2011.
39. Panero F, Novelli G, Zucco C et al. Fasting plasma C-peptide and micro and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009; 32: 301-305.
40. Wahren J, Ekberg K, Jornvall H. C-peptide is a bioactive peptide. Diabetologia 2007; 50: 503-509.